CogState releases details of UBC agreement

By Dylan Bushell-Embling
Tuesday, 29 July, 2008

Melbourne's CogState [ASX: CGS] has released the terms of its planned partnership with US pharmaceutical services company United BioSource Corporation [UBC], announced last week.

Under the arrangement, CogState and UBC will join forces to provide a comprehensive cognitive testing solution for use in clinical trials.

CogState markets six computerised diagnostic products to test cognitive function. It also has a therapeutic division with two compounds in early develop for Alzheimer's and Parkinson's diseases.

Under the agreement, UBC will buy a 15 per cent share in CogState, at a cost of around $800,000. UBC will also underwrite CogState's share rights issue.

Both companies will remain separate entities. In a statement to the stock exchange, CogState stressed that the arrangement will not necessitate any management changes or job losses.

Related News

SEQ koala population carries immunity to retrovirus

Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...

RSV immunisation program for babies slashes hospital stays

An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...

A targeted treatment option for psoriasis

New research from MedUni Vienna paves the way for the development of a therapy that not only...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd